MARKET

TNXP

TNXP

Tonix
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.730
+0.830
+92.22%
After Hours: 1.640 -0.09 -5.20% 16:04 02/27 EST
OPEN
1.970
PREV CLOSE
0.9000
HIGH
1.980
LOW
1.300
VOLUME
88.20M
TURNOVER
--
52 WEEK HIGH
42.00
52 WEEK LOW
0.3902
MARKET CAP
37.53M
P/E (TTM)
-0.0020
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of TNXP and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average TNXP stock price target is 1.250 with a high estimate of 1.250 and a low estimate of 1.250.

EPS

TNXP News

More
  • Southern Research collaborating to develop coronavirus vaccine
  • American City Business Journals · 6h ago
  • Mid-Afternoon Market Update: Dow Turns Negative; SmileDirectClub Shares Fall On Downbeat Q4 Results
  • Benzinga · 1d ago
  • Mid-Day Market Update: Dow Jumps Over 400 Points; Menlo Therapeutics Shares Plunge
  • Benzinga · 1d ago
  • Tonix To Develop Vaccine Against COVID-19 Virus, Shares Surge
  • Benzinga · 1d ago

Industry

Biotechnology & Medical Research
-3.81%
Pharmaceuticals & Medical Research
-3.01%

Hot Stocks

Symbol
Price
%Change
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%

About TNXP

Tonix Pharmaceuticals Holding Corp. is a clinical-stage pharmaceutical company. The Company's drug development programs are directed toward disorders affecting the central nervous system (CNS), and include fibromyalgia (FM), and post-traumatic stress disorder (PTSD). It is focused on developing a portfolio of product candidates, including one product candidate in clinical development for registration in two indications. TNX-102 SL (cyclobenzaprine hydrochloric acid (HCl) sublingual tablets), is a disintegrating tablet containing cyclobenzaprine (CBP) for sublingual administration. The Company has completed Phase IIb BESTFIT trial of TNX-102 SL for fibromyalgia. It is being evaluated in the Phase III AFFIRM study for the treatment of fibromyalgia. The Company is also conducting AtEase trial, which is a Phase II clinical trial of TNX-102 SL in military-related PTSD. It also has a pipeline of other product candidates, including TNX-301, a fixed dose combination drug product (CDP).
More

Webull offers kinds of Tonix Pharmaceuticals Holding Corp stock information, including NASDAQ:TNXP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TNXP stock news, and many more online research tools to help you make informed decisions.